Oragenics has activated a second clinical site at Alfred Hospital for its Phase IIa trial of ONP-002, a drug candidate for treating concussion and mild traumatic brain injury (mTBI). The trial, already enrolling patients at Mackay Base Hospital in Australia, aims to enroll 40 patients to evaluate ONP-002's effectiveness in reducing brain inflammation and injury symptoms. This drug could become the first FDA-approved pharmacological treatment for concussion, addressing a significant unmet medical need. Data from this trial is expected by the end of 2026, supporting a planned Phase IIb trial in the U.S.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
